BIOCRYST PHARMACEUTICALS INC

BCRX

BIOCRYST PHARMACEUTICALS INC

BCRX

Insider Sentiment (TTM):

Last Purchase:2024-05-30Last Sale:2026-05-18Shares Purchased (TTM):0Shares Sold (TTM):415,966

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:241,970,625Shares Outstanding:242,258,000Institutional Ownership Pct.:99.88%

Earnings Market Reaction:

Filing Date:2026-05-06Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Companies in Biological Products, (No Diagnostic Substances)

AMGN GILD SCLX BIIB MRNA RVMD

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Disposal Group Heldforsale Not Discontinued Operat…	-	-	0	29	-	-	-	-	-	-	-	-
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	172	90	84	88	105	105	97	78	84	111	151	146
Restricted Cash And Cash Equivalents At Carrying V…	1	0	1	0	0	0	1	2	2	2	2	2
Available For Sale Securities Debt Securities Curr…	-	-	-	-	-	216	233	194	252	278	247	264
Short Term Investments	67	185	129	172	190	216	-	-	-	-	-	-
Accounts Receivable Net Current	109	107	91	91	93	79	72	69	61	57	54	58
Inventory Net	6	5	5	5	7	8	8	4	30	29	30	27
Prepaid Expense And Other Assets Current	19	17	17	13	14	14	16	16	18	20	20	14
Assets Current	374	404	356	398	410	422	427	363	447	496	502	511
Inventory Noncurrent	28	24	23	22	25	23	22	25	-	0	-	-
Property Plant And Equipment Net	9	9	8	8	8	8	7	8	8	8	9	8
Long Term Investments	21	61	40	10	21	20	19	64	-	0	0	3
Other Assets Noncurrent	20	6	4	4	5	5	16	12	13	0	11	7
Assets	465	514	446	457	480	490	491	472	468	517	523	530
Liabilities And Stockhold…
Deferred Revenue Current	-	-	-	-	-	-	-	-	-	0	1	2
Liabilities Current
Accounts Payable Current	11	16	6	9	10	12	13	8	12	21	11	14
Accrued Liabilities Current	119	126	119	107	93	113	104	90	79	103	77	75
Operating Lease Liability Current	2	0	0	0	1	1	1	1	1	1	2	3
Finance Lease Liability Current	1	1	1	2	2	2	2	2	2	2	-	-
Contract With Customer Liability Current	5	-	-	-	-	-	-	-	-	-	-	-
Liabilities Current	195	196	190	177	140	160	154	129	120	150	91	93
Operating Lease Liability Noncurrent	11	9	8	8	8	8	8	8	9	8	10	6
Finance Lease Liability Noncurrent	1	1	2	2	2	2	2	2	3	3	-	-
Long Term Debt Noncurrent	395	0	194	243	315	315	314	314	308	303	298	293
Contract With Customer Liability Noncurrent	9	-	-	-	-	-	-	-	-	-	-	-
Liabilities	1,019	633	834	879	932	966	960	-	-	972	-	-
Stockholders Equity
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	3	2	2	2	2	2	2	2	2	2	2	2
Additional Paid In Capital	1,672	1,385	1,361	1,340	1,315	1,291	1,270	1,251	1,238	1,222	1,206	1,192
Accumulated Other Comprehensive Income Loss Net Of…	-0	0	1	2	1	1	2	1	1	1	1	1
Retained Earnings Accumulated Deficit	-2,228	-1,506	-1,752	-1,765	-1,770	-1,770	-1,743	-1,729	-1,717	-1,681	-1,619	-1,583
Stockholders Equity	-554	-119	-388	-422	-452	-476	-469	-476	-476	-456	-411	-389
Liabilities And Stockholders Equity	465	514	446	457	480	490	491	472	468	517	523	530
Preferred Stock Par Or Stated Value Per Share	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01
Preferred Stock Shares Authorized	5	5	5	5	5	5	5	5	5	5	5	5
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	-	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	-	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01
Common Stock Shares Authorized	450	450	450	450	450	450	450	450	450	450	450	450
Common Stock Shares Issued	254	213	211	210	209	209	207	207	206	206	190	189
Shares Outstanding	254	213	211	210	209	209	207	207	206	206	190	189

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	0.91%	12.57%	-	-	-	-	-	-	-	-	-	-
2025	4.67%	-8.86%	-16.75%	-0.60%	-8.73%	-13.88%	6.21%	12.87%	0.44%	22.78%	20.25%	14.18%
2024	22.81%	17.49%	49.24%	10.42%	-3.18%	1.02%	6.23%	9.21%	8.22%	-3.62%	-10.63%	23.67%
2023	-1.65%	-17.08%	-9.54%	8.49%	5.51%	-20.86%	12.43%	9.51%	-0.55%	-14.65%	-24.53%	6.98%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Metrics	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Liquidity Ratios
Current Ratio	1.91	2.06	1.87	2.25	2.93	2.63	2.78	2.82	3.73	3.31	5.54	5.47
Quick Ratio	1.78	1.95	1.76	2.15	2.78	2.49	2.63	2.65	3.33	2.99	4.99	5.03
Working Capital	178.23M	208.28M	165.45M	221.30M	270.12M	261.58M	273.56M	234.39M	327.18M	345.98M	411.70M	417.56M
Leverage & Debt
Debt to Equity	-1.84	-5.32	-2.15	-2.08	-2.06	-2.03	-2.05	-0.27	-0.25	-2.13	-0.22	-0.24
Interest Coverage TTM	-5.08	4.32	0.85	0.57	0.34	-0.03	-0.41	-0.60	-0.85	-0.96	-0.97	-1.05
Debt Ratio	2.19	1.23	1.87	1.92	1.94	1.97	1.95	0.27	0.26	1.88	0.17	0.18
Efficiency & Turnover
Asset Turnover TTM	1.87	1.74	1.28	1.20	1.06	0.89	0.81	0.76	0.73	0.62	0.59	0.59
Days Sales Outstanding TTM	41.76	38.78	49.83	52.36	55.81	55.08	55.78	60.36	56.09	59.22	55.32	59.01
Receivables Turnover TTM	8.74	9.41	7.32	6.97	6.54	6.63	6.54	6.05	6.51	6.16	6.60	6.18
Per Share Metrics
Diluted EPS TTM	-1.89	1.21	-0.04	-0.16	-0.25	-0.43	-0.60	-0.71	-1.01	-1.18	-1.25	-1.28
Free Cash Flow Per Share TTM	1.28	1.64	0.23	0.08	-0.13	-0.26	-0.27	-0.42	-0.50	-0.51	-0.59	-0.66
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	97.76%	97.82%	97.39%	97.01%	96.91%	97.28%	98.13%	98.53%	98.65%	98.65%	98.33%	97.47%
Operating Profit Margin TTM	-43.11%	38.98%	12.69%	9.72%	6.59%	-0.56%	-9.87%	-15.78%	-25.26%	-31.29%	-33.81%	-36.81%
Net Profit Margin TTM	-51.71%	30.16%	-1.46%	-6.41%	-10.62%	-19.72%	-30.01%	-38.18%	-58.69%	-68.36%	-74.43%	-79.15%
Growth Metrics
Net Revenue Growth (1Y)	75.92%	94.10%	45.38%	45.85%	41.67%	36.00%	29.92%	24.65%	22.68%	22.37%	33.18%	50.60%
Net Income Growth (1Y)	756.52%	-396.87%	-92.91%	-75.53%	-74.37%	-60.77%	-47.61%	-39.88%	-7.81%	-8.33%	22.24%	15.78%
EPS Growth (1Y)	638.52%	-392.35%	-93.02%	-75.89%	-74.71%	-63.52%	-51.98%	-44.92%	-15.66%	-11.33%	20.00%	13.63%
Valuation Metrics
P/E TTM	-5.04	6.20	-181.71	-52.57	-29.30	-17.49	-12.70	-8.74	-5.02	-5.08	-5.68	-5.49
P/B TTM	-4.16	-13.74	-4.11	-4.45	-3.47	-3.27	-3.36	-2.68	-2.20	-2.53	-3.27	-3.43
P/S TTM	2.60	1.87	2.66	3.37	3.11	3.45	3.81	3.34	2.95	3.47	4.23	4.34
Market Cap	2.31B	1.64B	1.60B	1.88B	1.57B	1.55B	1.57B	1.28B	1.05B	1.15B	1.34B	1.33B
Enterprise Value	2.53B	1.55B	1.71B	2.03B	1.78B	1.76B	1.79B	1.51B	1.27B	1.35B	1.49B	1.48B
Calculated Values
Free Cash Flow TTM	310.37M	344.90M	47.86M	15.76M	-26.89M	-53.14M	-56.73M	-85.80M	-103.56M	-97.31M	-112.21M	-123.95M
Net Debt	223.05M	-88.58M	111.72M	156.38M	210.33M	210.38M	219.33M	237.09M	225.79M	194.18M	147.09M	146.96M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-05-18Sale

Owner: Mckee, Amy E

Title: -

Shares: 11,180

Price/Share: $8.97

Value: $100,284.60

Shares Owned: 31,252

Relationship: Director

Ownership: Direct

2026-05-13Sale

Owner: Barnes, Alane P

Title: Chief Legal Officer

Shares: 62,500

Price/Share: $9.54

Value: $596,250.00

Shares Owned: 400,703

Relationship: Officer

Ownership: Direct

2026-03-20Sale

Owner: Heggie, Theresa

Title: -

Shares: 49,933

Price/Share: $10.11

Value: $504,822.63

Shares Owned: 65,352

Relationship: Director

Ownership: Direct

2026-03-16Sale

Owner: Barnes, Alane P

Title: Chief Legal Officer

Shares: 150,000

Price/Share: $9.15

Value: $1,372,500.00

Shares Owned: 400,703

Relationship: Officer

Ownership: Direct

2025-12-22Sale

Owner: Barnes, Alane P

Title: Chief Legal Officer

Shares: 21,773

Price/Share: $7.65

Value: $166,563.45

Shares Owned: 398,751

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-05-18	Mckee, Amy E	Director	-	Direct	Sale	11,180	8.97	$100,284.60	31,252	4
2026-05-13	Barnes, Alane P	Officer	Chief Legal Officer	Direct	Sale	62,500	9.54	$596,250.00	400,703	4
2026-03-20	Heggie, Theresa	Director	-	Direct	Sale	49,933	10.11	$504,822.63	65,352	4
2026-03-16	Barnes, Alane P	Officer	Chief Legal Officer	Direct	Sale	150,000	9.15	$1,372,500.00	400,703	4
2025-12-22	Barnes, Alane P	Officer	Chief Legal Officer	Direct	Sale	21,773	7.65	$166,563.45	398,751	4
2025-12-15	Barnes, Alane P	Officer	Chief Legal Officer	Direct	Sale	21,210	7.65	$162,256.50	315,726	4
2025-12-03	Barnes, Alane P	Officer	Chief Legal Officer	Direct	Sale	19,770	7.65	$151,240.50	345,476	4
2025-11-13	Sanders, Machelle	Director	-	Direct	Sale	9,600	7.14	$68,544.00	30,642	4
2025-08-13	Heggie, Theresa	Director	-	Direct	Sale	70,000	8.51	$595,700.00	65,352	4
2024-12-13	Hutson, Nancy J	Director	-	Direct	Sale	7,000	7.54	$52,780.00	86,638	4
2024-06-24	Mckee, Amy E	Director	-	Direct	Sale	8,600	6.32	$54,352.00	27,831	4
2024-06-17	Sanders, Machelle	Director	-	Direct	Sale	4,689	6.00	$28,134.00	27,742	4
2024-06-14	Heggie, Theresa	Director	-	Direct	Sale	6,698	6.11	$40,924.78	52,852	4
2024-05-30	Levin, Alan G	Director	-	Direct	Purchase	7,861	6.36	$49,995.96	44,951	4
2024-05-24	Aselage, Steve	Director	-	Indirect	Purchase	2,500	6.40	$16,000.00	2,500	4
2024-05-20	Hutson, Nancy J	Director	-	Direct	Purchase	5,000	6.38	$31,900.00	86,818	4
2024-05-20	Milano, Vincent	Director	-	Direct	Purchase	15,000	6.25	$93,750.00	66,997	4
2024-05-14	Doyle, Anthony	Officer	Chief Financial Officer	Direct	Purchase	36,300	5.57	$202,191.00	266,744	4
2024-05-14	Thackray, Helen M.	Officer	Chief R&D Officer	Direct	Purchase	30,000	5.86	$175,800.00	272,139	4
2024-05-13	Stonehouse, Jon P	Director,Officer	President & CEO	Direct	Purchase	30,000	5.55	$166,500.00	1,127,770	4
2024-05-13	Gayer, Charles K	Officer	Chief Commercial Officer	Direct	Purchase	30,000	5.47	$164,100.00	307,533	4
2024-05-13	Galson, Steven K	Director	-	Direct	Purchase	21,940	5.49	$120,450.60	51,551	4
2024-05-13	Barnes, Alane P	Officer	Chief Legal Officer	Direct	Purchase	5,000	5.53	$27,650.00	300,762	4
2023-06-15	Sanders, Machelle	Director	-	Direct	Sale	4,000	7.98	$31,920.00	25,611	4
2023-06-14	Hutson, Nancy J	Director	-	Direct	Sale	12,866	8.04	$103,442.64	81,818	4
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

99.88%

Inst. Shares: 241,970,625

Shares Outstanding: 242,258,000

2025-12-31

96.99%

Inst. Shares: 203,569,476

Shares Outstanding: 209,893,000

2025-09-30

90.00%

Inst. Shares: 189,156,064

Shares Outstanding: 210,176,000

2025-06-30

90.71%

Inst. Shares: 190,060,915

Shares Outstanding: 209,519,000

2025-03-31

80.22%

Inst. Shares: 167,561,728

Shares Outstanding: 208,882,000

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	241,970,625	242,258,000	99.88%
2025-12-31	203,569,476	209,893,000	96.99%
2025-09-30	189,156,064	210,176,000	90.00%
2025-06-30	190,060,915	209,519,000	90.71%
2025-03-31	167,561,728	208,882,000	80.22%
2024-12-31	162,124,799	206,696,000	78.44%
2024-09-30	164,416,049	206,905,000	79.46%
2024-06-30	166,918,612	206,425,000	80.86%
2024-03-31	172,301,805	206,064,000	83.62%
2023-12-31	170,082,154	192,198,000	88.49%
2023-09-30	166,628,751	189,644,000	87.86%
2023-06-30	160,542,738	189,118,000	84.89%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

BIOCRYST PHARMACEUTICALS INC (BCRX) — SEC Financial Statements & Analysis

BIOCRYST PHARMACEUTICALS INC (BCRX) is a biological products, (no diagnostic substances) company, incorporated in DE. BIOCRYST PHARMACEUTICALS INC trades on Nasdaq as: BCRX. Based on its latest SEC filing (Form 10-Q, period ending 2026-03-31), BIOCRYST PHARMACEUTICALS INC reported a 75.92% year-over-year revenue growth, a Gross Profit Margin of 97.76% (TTM), a Debt-to-Equity ratio of -1.84x, a Price-to-Sales (P/S) ratio of 2.60x (TTM), a Price-to-Book (P/B) ratio of -4.16 (TTM), at a market cap of $2.31B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 75.92%
Gross Profit Margin TTM: 97.76%
Debt To Equity: -1.84x
P/S TTM: 2.60x
P/B TTM: -4.16
Market Cap: $2.31B

Data as of 2026-03-31 · Source: SEC EDGAR

Frequently Asked Questions

What industry is BIOCRYST PHARMACEUTICALS INC in?

BIOCRYST PHARMACEUTICALS INC (BCRX) operates in the Biological Products, (No Diagnostic Substances) industry.

What is BCRX's market cap?

BIOCRYST PHARMACEUTICALS INC (BCRX) has a market capitalization of $2.31B as of 2026-03-31.

What exchange does BCRX trade on?

BIOCRYST PHARMACEUTICALS INC (BCRX) trades on the Nasdaq.

Where is BIOCRYST PHARMACEUTICALS INC incorporated?

BIOCRYST PHARMACEUTICALS INC is incorporated in DE.

BIOCRYST PHARMACEUTICALS INC (BCRX) — SEC Financial Statements & Analysis

Frequently Asked Questions

Research Faster.Invest Smarter.

Research Faster.
Invest Smarter.